$ELVN

$41.49 -$0.03 (0.07%) Close

$ELVN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 73.3M shares outstanding

Who owns ELVN?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 66.0%

FMR LLC 13.7% · Orbimed Advisors LLC 9.3%

Institutional ownership

100.0%

+14.3 pts vs last qtr

Institutional holders

209

+40 vs last qtr

Net shares bought

+17.4M

by institutions in Q2 2026

New / sold out

63 / 23

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

FMR LLC +3.2M
Price T Rowe Associates Inc /MD/ +2.8M

Biggest sellers in Q2 2026

Venrock Adviser, LLC −1.2M
Orbimed Advisors LLC −1.2M

Who is planning to sell?

Notices of proposed sale, last 12 months

$90.3M

40 notices from 13 people

Shares covered

2.4M

3.21% of the company

Arranged in advance

35%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

OrbiMed Private Investments VII, LP Shareholder $47.7M
Derynck Mika K Director 10b5-1 $9.22M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2021–FY2025

+2357.1%

+122.64% a year

Each share's claim on the business

−95.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $72.2M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years48% 1–3 years28% Under 1 year24%

Quarterly turnover

25.0%

of institutional shares changed hands

Top 10 managers, median time held

3.3 years

Super Investors

Investment managers reporting ELVN on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
F FMR LLC	10.0M	13.68%	+3.2M (+46.8%)	2023	0.0%
Shares held by quarter Peak holding10.0M (Q2'26) Change over 8 quarters+3.7M Share of the company13.680% FMR LLC's full portfolio →
OA Orbimed Advisors LLC 13D · 9.5%	6.8M	9.25%	−1.2M (−14.9%)	2023	6.4%
Shares held by quarter Peak holding8.0M (Q3'24) Change over 8 quarters−1.2M Share of the company9.250% Disclosed stake13D · 9.5% Orbimed Advisors LLC's full portfolio →

FMR LLC

10.0M

% of company

13.68%

Change vs last qtr

+3.2M (+46.8%)

Held since

2023

Orbimed Advisors LLC

13D · 9.5%

6.8M

% of company

9.25%

Change vs last qtr

−1.2M (−14.9%)

Held since

2023

28 more super investors behind a free account

See every manager holding Enliven Therapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ELVN on Form N-PORT; together they hold 29.7% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$95.6M	1.9M	2.57%	0.00%	June 30, 2026
SH Select Health Care Portfolio Fidelity Select Portfolios	$74.1M	1.3M	1.75%	1.10%	August 31, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$95.6M

% of company

2.57%

% of the fund

0.00%

As of

June 30, 2026

Select Health Care Portfolio

Fidelity Select Portfolios

Position value

$74.1M

% of company

1.75%

% of the fund

1.10%

As of

August 31, 2026

23 more funds behind a free account

See every fund holding Enliven Therapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
OC Orbimed Capital GP Vii LLC 5%+ holder 13D · 9.2%	6.6M	8.95%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company8.950% Disclosed stake13D · 9.2% View the 13D/G filing →
KS Kintz Samuel Insider	890.4K	1.22%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.220% Kintz Samuel's insider activity →

Orbimed Capital GP Vii LLC

5%+ holder13D · 9.2%

6.6M

% of company

8.95%

Change vs last qtr

—

Held since

—

Kintz Samuel

Insider

890.4K

% of company

1.22%

Change vs last qtr

—

Held since

—

7 more holders behind a free account

See every insider and 5%+ holder of Enliven Therapeutics, Inc..

Comments